An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 45-53

  Ravichandran, Kameswaran ^a   Zafar, Iram ^a   Ozkok, Abdullah ^a   Edelstein, Charles L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

apoptosis; mTOR kinase; polycystic kidney; proliferation; sirolimus

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; BIOLOGICAL MARKER; CASPASE 3; CELL PROTEIN; CXCL1 CHEMOKINE; INTERLEUKIN 1; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NITROGEN; PROTEIN KINASE B; PROTEIN PS6; RAPAMYCIN; SERINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; INDOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOBLOTTING; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE CELL; MALE; NICK END LABELING; NONHUMAN; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; POLYCYSTIC KIDNEY DISEASES; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; BLOOD UREA NITROGEN; CASPASE 3; CELL PROLIFERATION; DISEASE PROGRESSION; IMMUNOBLOTTING; INDOLES; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MULTIPROTEIN COMPLEXES; POLYCYSTIC KIDNEY DISEASES; PROTEIN KINASE INHIBITORS; PURINES; RATS; RATS, SPRAGUE-DAWLEY; TOR SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922465709     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu296     Document Type: Article

References (43)

1. Feldman ME, Apsel B, Uotila A et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7: e38
2. Shillingford JM, Piontek KB, Germino GG et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 2010; 21: 489-497
3. Zafar I, Ravichandran K, Belibi F et al. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int 2010; 78: 754-761
4. Belibi F, Ravichandran K, Zafar I et al. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol 2011; 300: F236-F244
5. Fischer DC, Jacoby U, Pape L et al. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant 2009; 24: 1819-1827
6. Liu Q, Thoreen C, Wang J et al. mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg 2011; 6: 47-55
7. Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840
8. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829
9. Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350: 151-164
10. Albert S, Serova M, Dreyer C et al. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010; 19: 919-930
11. Janes MR, Limon JJ, So L et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205-213
12. Cowley BD, Jr, Gudapaty S, Kraybill AL et al. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993; 43: 522-534
13. Tao Y, Kim J, Schrier RW et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD). J Am Soc Nephrol 2005; 16: 46-51
14. Brown JH, Bihoreau MT, Hoffmann S et al. Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. J Am Soc Nephrol 2005; 9: 937-945
15. Nagao S, Morita M, Kugita M et al. Polycystic kidney disease in Han: SPRD Cy rats is associated with elevated expression and mislocalization of Sam Cystin. Am J Physiol Renal Physiol 2010; 299: F1078-F1086
16. Cowley BD, Jr, Rupp JC, Muessel MJ et al. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 1997; 29: 265-272
17. Dursun B, He Z, Somerset H et al. Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am J Physiol Renal Physiol 2006; 291: F578-F587
18. Melnikov VY, Faubel SG, Siegmund B et al. Neutrophil-independent mechanisms of caspase-1-And IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 2002; 110: 1083-1091
19. Tao Y, Kim J, Faubel S et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease (PKD). Proc Natl Acad Sci USA 2005; 102: 6954-6959
20. Tao Y, Zafar I, Kim J et al. Deletion of the caspase-3 gene markedly prolongs survival in the cpk mouse model of polycystic kidney disease (PKD). J Am Soc Nephrol 2007; 19: 749-755
21. Hoang B, Frost P, Shi Y et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116: 4560-4568
22. Shor B, Gibbons JJ, Abraham RT et al. Targeting mTOR globally in cancer; thinking beyond rapamycin. Cell Cycle 2009; 8: 3831-3837
23. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484
24. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101
25. Ta MH, Harris DC, Rangan GK. Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology (Carlton) 2013; 18: 317-330
26. Lee DF, Kuo HP, Chen CT et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007; 130: 440-455
27. Katholnig K, Linke M, Pham H et al. Immune responses of macrophages and dendritic cells regulated by mTOR signalling. Biochem Soc Trans 2013; 41: 927-933
28. Pan H, Xu LH, Ouyang DY et al. The second-generation mTOR kinase inhibitor INK128 exhibits anti-inflammatory activity in lipopolysaccharideactivated RAW264.7 cells. Inflammation 2014; 37: 756-765
29. Weichhart T, Haidinger M, Katholnig K et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 2011; 117: 4273-4283
30. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011; 23: 744-755
31. Brown J, Wang H, Suttles J et al. Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J Biol Chem 2011; 286: 44295-44305
32. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471
33. Edelstein CL. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)? Cell Cycle 2005; 4: e141-e145
34. Natoli TA, Smith LA, Rogers KA et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 2010; 16: 788-792
35. Trudel M, Barisoni L, Lanoix J et al. Polycystic kidney disease in SBM transgenic mice: role of c-myc in disease induction and progression. Am J Pathol 1998; 152: 219-229
36. Schaffner DL, Barrios R, Massey C et al. Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol 1993; 142: 1051-1060
37. Chang MY, Parker E, Ibrahim S et al. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol Dial Transplant 2006; 21: 2078-2084
38. Zafar I, Belibi FA, He Z et al. Long-term rapamycin therapy in the Han: SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 2009; 24: 2349-2353
39. Boletta A. Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics 2009; 2: 6
40. Boletta A, Qian F, Onuchic LF et al. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol Cell 2000; 6: 1267-1273
41. Jiang Q, Weiss JM, Back T et al. mTOR kinase inhibitor AZD8055 enhances immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res 2011; 71: 4074-4084
42. Chresta CM, Davies BR, Hickson I et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288-298
43. Liu Q, Chang JW, Wang J et al. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1, 6]naphthyridin-2 (1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem2010; 53: 7146-7155